论文部分内容阅读
目的探讨瘤内注射胶体~(32)磷治疗肝癌的可行性。方法送肿瘤及各主要脏器作病理检查,查肝、肾功能及血常规,则A组大鼠胶体~(32)磷的体内分布。结果胶体~(32)磷注射后主要聚集于肿瘤及其邻近肝区,除第7天有一过性ALT增高外,未见其它毒副作用。治疗后肿瘤体积缩小,生长率降低,与B组(30天时)及C组比较差异有显著意义(P<0.01)。结论瘤内注射胶体~(32)磷治疗肝癌是一种安全有效的方法
Objective To investigate the feasibility of intratumoral injection of colloidal (32) phosphorus for liver cancer. Methods Tumor and main organs were sent for pathological examination, liver function, renal function and blood routine examination. The distribution of colloidal (32) phosphorus in group A rats was analyzed. RESULTS: Colloidal (32) phosphorus was mainly accumulated in the tumor and its adjacent liver after injection. Except for a transient increase in ALT on the 7th day, no other side effects were observed. After treatment, the tumor volume decreased and the growth rate decreased. There was a significant difference between group B (at 30 days) and group C (P<0.01). Conclusion Intratumoral injection of colloidal (32) phosphorus is a safe and effective method for liver cancer treatment